Future randomized clinical trials should report absolute Psoriasis Area and Severity Index at follow-up, in order to improve the transferability between trial data and real-world data.
According to results from the ECLIPSE trial, treatment with guselkumab was found to be superior to secukinumab in adult patients with moderate-to-severe plaque psoriasis based on 90% or better improvement in patients’ Psoriasis Area and Severity Index score compared to baseline (PASI 90 response).
Dietary intervention may reduce psoriasis severity in patients with obesity and probably improves quality of life and reduces BMI.
The FDA has expanded the approval for Taclonex Topical Suspension and Enstilar Foam, two plaque psoriasis therapies to include younger patients.
The first evaluation of the effects of brodalumab treatment in patients with and without obesity with psoriasis found no difference in safety or efficacy between the two patient populations.
A clinical guideline for the use of phototherapy for the care and management of adult patients with psoriasis developed by the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) has been published.
Antibody-based therapies such as ustekinumab can causally decrease aortic vascular inflammation.
In this first report of a head-to-head trial comparing risankizumab and adalimumab, the former agent was found to demonstrate greater efficacy in patients with moderate to severe plaque psoriasis.
A higher prevalence of NAFLD was observed among patients with psoriasis without arthritis compared with patients with psoriatic arthritis.
Ixekizumab may be the answer for patients with plaque psoriasis who have failed on other biologics.
